CClinicalTrials.gg
CompletedNCT06143020Updated Nov 17, 2025

Effect of ESPB on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction

An interventional study of Erector spinae plane block in Mammary Cancer, Erector Spinae Plane Block and Postoperative Pain, sponsored by Fudan University. Completed at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Fudan University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Nowadays, the incidence of breast cancer is the first number of malignant tumors, and the primary treatment method is surgery.With the development of medical technology and concept, radical mastectomy combined breast reconstruction are becoming more and more popular.But the reconstruction caused greater trauma and more severe postoperative pain.ESPB is a new nerve block method which thought to reduce pain after thoracic and breast surgery.However, there are few studies on radical mastectomy combined breast reconstruction. So, this randomized controlled study is conducted to explore its impact on postoperative pain and thus provide more data guidance for clinical.

Read the detailed description

Patients: 100 breast cancer patients who are planned radical mastectomy combined breast reconstruction Intervention: General anesthesia + erector spinae plane block Control : General anesthesia Outcome: NRS(Numerical rating scale) of postoperative pain at the sixth hour Study:RCT

02

Conditions studied

  • Mammary Cancer
  • Erector Spinae Plane Block
  • Postoperative Pain

Keywords

  • Mammary Cancer
  • implant reconstruction
  • erector spinae plane block
  • Postoperative Pain
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 100 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • patients scheduled for an radical mastectomy and implant reconstruction surgery
  • Patients with American Society of Anesthesiologists (ASA) physical status I-II,
  • aged 18-70 years

Exclusion criteria

Exclusion Criteria:

  • coagulation disorders,
  • known allergy to study drugs,
  • obesity (body mass index > 35 kg/m2),
  • infection at the injection site,
  • chronic opioid consumption, and an inability to use patient-controlled analgesia (PCA) device,
  • patient refuse
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Erector spinae plane block group

    Before surgery, an ultrasound-guided ESPB was performed. 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Ropivacaine is produced by AstraZeneca AB under the trade name of Naropin, and the specifications are 75 mg / 10 ml. Dexmedetomidine is produced by HengRui medical China and the specifications are 100μg / 1 ml。

    Procedure: Erector spinae plane block

  • No intervention
    Control group

    Control groups do not receive additional analgesia.

Interventions

  • ProcedureErector spinae plane block

    In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.

    Also known as: Ultrasound-guided erector spinae plane block

06

What researchers measure

Primary outcomes

  1. Post-operative acute pain score at 6 hours

    11-point numerical rating scale(0=no pain, 10=worst pain) at 6th hour following the surgery

    Time frame: 6 hours After surgery

Secondary outcomes

  1. Postoperative quality of recovery score

    The QoR-15 will be used to evaluate postoperative quality of recovery from 15 dimensions. The QoR-15 scale is a global measurement of postoperative recovery, consisting of 15 items with 10 points each, with a total score ranging from 0 (QoR very poor) to 150 (QoR very good).

    Time frame: 24 to 72 hours after the surgery

  2. Post-operative acute pain score

    Pain scores at other time points except for the primary outcome. The numerical rating scale (NRS) is a line with numbers from 0 to 10 are spaced evenly across the page. And the NRS is bounded at the left-most end with "no pain" and at the right-most end with "worst pain imaginable". Pain levels below "4" are considered mild, "4-7" is moderate pain, and anything above "7" is considered severe pain. Patients are instructed to circle the number that represents the amount of pain that they are experiencing at the time of the evaluation. The movement status refers to maximum mobility of the upper arm of the surgical side. Remedial pain relief measures are initiated when the Numeric Rating Scale (NRS) score exceeds 4.

    Time frame: 1h, 12h,24, 48h, 72h after the surgery, separately.

  3. Cumulative opioid consumption after surgery

    Cumulative opioid consumption after surgery

    Time frame: 48 hours after the surgery

  4. AUC of postoperative pain score

    Area under the curve(AUC) of pain score 72 hours after surgery

    Time frame: 72 hours after the surgery

Other outcomes

  1. Number of patients with nausea and vomiting

    Number of patients who experienced nausea and vomiting after surgery.

    Time frame: 24 to 72 hours after the surgery

  2. Intraoperative hemodynamic data

    Including mean blood pressure(mmHg), heart rate(beats/min) during the surgery.

    Time frame: During the whole surgery process.

  3. The number of patients receiving rescue analgesia.

    The number of patients receiving rescue analgesia.

    Time frame: 24 to 72 hours after the surgery

07

Study locations

1 site
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06143020
Lead sponsor
Fudan University
Responsible party
Jun Zhang (Director of the department of anaesthesiology, Shanghai cancer center, Fudan University) — Principal investigator
First posted
Nov 22, 2023
Start date
Nov 20, 2023
Primary completion
Aug 20, 2025
Completion
Aug 25, 2025
Last update
Nov 17, 2025

Study contacts

Jun Zhang, PhD
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion